Balyasny Asset Management (BAM) is a diversified global multi-strategy investment firm founded in 2001 and headquartered in Chicago. The firm manages hedge fund strategies across equities, macro, credit, and commodities, and has expanded into growth-stage venture investing through its BAM Corner Point affiliate, focusing on enterprise technology companies.
49% of their portfolio is in Biotech & Life Sciences. Deal activity increased 600% year-over-year (7 deals in the last 12 months). Average disclosed round size is $175.7M (across 32 rounds with reported amounts).
Portfolio
27
Fund Size
—
Top Stage
Series C
Last 12 Mo
7
Team
Anita Nassar
Partner, Senior Managing Director, Global Head of Client Relationship Group
Alex Lurye
Partner & Chief Risk Officer
Bill Wappler
Partner & Global Director of Research
Caesar Yuan
Partner & Portfolio Manager
Jing Ge
Partner & Portfolio Manager
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
Portfolio
| Company | Round | Amount | Date |
|---|---|---|---|
 Solve Therapeutics | Bridge | $120M | Sep 2026 |
 Coultreon Biopharma | Series A | $125M | Apr 2026 |
 Ovid Therapeutics Inc. | Unknown | $60M | Mar 2026 |
 Serapha Bio | Series A | $138M | Jan 2026 |
| Solve Therapeutics | Unknown | $120M | Jan 2026 |
 Coultreon Biopharma | Series A | $125M | Jan 2026 |
| Coultreon Biopharma | Series A | $125M | Jan 2026 |
| AAvere Therapeutics | Unknown | $320M | Jan 2026 |
 Sagimet Biosciences | Series C | $175M | Jan 2026 |
 Ambros Therapeutics | Series A | $125M | Dec 2025 |
 Aspen Neuroscience | Series C | $115M | Nov 2025 |
 Aspen Neuroscience | Series C | $115M | Nov 2025 |
| Solve Therapeutics | Series D | $120M | Nov 2025 |
 Forterra | Growth | — | Nov 2025 |
| Forterra | Series C | $238M | May 2025 |
 Damora Therapeutics | Unknown | $284.9M | Jan 2025 |
| Ambros Therapeutics | Series A | $125M | Jan 2025 |
 RapidSOS | Growth | $150M | Mar 2024 |
 Harness | Series D | $230M | Apr 2022 |
| HHarness.io | Series D | $230M | Apr 2022 |
 Obsidian Therapeutics | Series B | $115M | Sep 2021 |
 Nature's Fynd | Series C | $350M | Jul 2021 |
 FlyHomes | Series C | $150M | Jun 2021 |
 MasterClass | Series F | $225M | May 2021 |
| HHARNESS INC. | Series D | $230M | Jan 2021 |
Top Co-Investors
Last updated: 7 October 2026